Page 2 - Marek Ciszewski News Today

REDWOOD CITY, Calif., July 21, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that...

First formal distribution agreement for YUSIMRY™, a biosimilar of Humira®, at $995 per carton (two 40 mg/0.8 mL autoinjectors) representing a discount of...

YUSIMRY™ (adalimumab-aqvh) product image REDWOOD CITY, Calif., July 13, 2023 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and…

REDWOOD CITY - Coherus BioSciences, Inc. , today announced that YUSIMRY is now available for commercial sale in the United States at a list price of $995 per carton for two 40 mg/0.8 mL...

–$995 per carton represents a discount of more than 85% compared to Humira® – – YUSIMRY™ meets high unmet need by providing patients, employers, physicians and payers...

Coherus to Acquire Surface Oncology - Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple... | June 16, 2023

– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing... | June 16, 2023

–Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiplenext-generationimmunotherapies in clinical development funded bygrowing revenues –

– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients...

– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients – – No treatments are... | June 5, 2023